Executive Summary
The report "Emerging Pharmaceutical Markets Globally" provides an exhaustive overview of the pharmaceutical markets in the E7 countries (Brazil, Russia, India, China, Mexico, Turkey and Indonesia). This Report provides a detailed account of the factors that are redefining the structure and composition of the global pharmaceutical market and causing a shift in growth from the mature markets to the emerging ones.
Statistics and analysis regarding market size, growth, structure, exports and imports, therapy mix, share of branded and generic drugs, healthcare financing, market share of key players, as well as key drivers and restraints and trends in technology development have been thoroughly analyzed in this report.
The report also envisages the fact that the markets in the E7 have huge differences as compared to the developed markets in terms of traditional therapies, intellectual property, health insurance scenario and so forth. Thus, it provides valuable information to pharmaceutical companies and investors looking to foray into these markets and help them devise strategies according to the E7 markets.
Key Findings
The E7 Pharmaceutical markets are expected to grow at a CAGR 11.5% between 2007 and 2012 reaching revenues worth nearly US$ 116 Billion. In contrast the G7 Pharmaceutical markets are projected to grow at CAGR 4.95% between the same periods.
The pharmaceutical markets in India, China and Turkey are expected to grow the fastest among all the E7 nations.
The E7 nations are expected to account for nearly half of the 6.99 Billion global populations in 2012.
Cardiovascular, cancer and other chronic diseases have taken over communicable diseases as the biggest killers in these nations.
The Pharmaceutical market in most of these regions is still dominated by acute therapies, but with the growth rate of chronic therapies far exceeding that of acute therapies, the therapy mix of the market will be much different in the next five years from what it is today.
The markets in India, China, Russia and Indonesia are dominated by generics. Generics however have a lower penetration in Brazil, Mexico and Turkey.
Inadequate protection of intellectual property and large-scale prevalence of counterfeit drugs remains a major challenge faced by the pharmaceutical industry in these regions.
Key Issues & Facts
Evaluation of past, current and future market trends.
Evaluation of the market by segment.
Discussion about the major drivers of the pharmaceutical market.
Analysis of the opportunities created by the market.
Analysis of the major challenges faced by the market.
Competitive landscape of the market.
Key Players Analyzed
This section provides the overview, key facts and financial information of prominent players in the E7 pharmaceutical market like GlaxoSmithKline, Sanofi-Aventis, Pfizer Inc., Novartis, and AstraZeneca.
Research Methodology
Information Sources
Information has been sourced from books, newspapers, trade journals, and white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to more than 3000 paid databases.
Analysis Methods
The analysis methods include ratio analysis, historical trend analysis, and linear regression analysis using software tools, judgmental forecasting, and cause and effect analysis.
Table of Contents
Chapter 1 Analyst View
Chapter 2 Global Pharmaceutical Market
2.1 Market Size
2.2 Mature Markets - G7 Countries
2.3 Emerging Markets - E7 Countries
2.4 E7 Countries to Grow Strongly
Chapter 3 Why E7 Pharmaceutical Market
3.1 Economic Growth
3.2 Income Level
3.3 Population Base
3.4 Prevalence of Lifestyle-related Diseases
3.5 Medical & Distribution Infrastructure
3.6 Health Insurance
Chapter 4 Industry Performance
4.1 Brazil (Past, Present & Future Scenario)
4.1.1 Macroeconomic Indicators
4.1.2 Population Profile
4.1.3 Disease Profile
4.1.4 Healthcare Spending & Financing
4.1.5 Pharmaceutical Market
4.1.6 Import & Export
4.1.7 Generic Drugs
4.1.8 Therapy Areas
4.1.9 Key Players
4.2 Russia (Past, Present & Future Scenario)
4.2.1 Macroeconomic Indicators
4.2.2 Population Profile
4.2.3 Disease Profile
4.2.4 Healthcare Spending & Financing
4.2.5 Pharmaceutical Market
4.2.6 Import
4.2.7 Branded & Generic Drugs
4.2.8 Therapy Areas
4.2.9 Key Players
4.3 India (Past, Present & Future Scenario)
4.3.1 Macroeconomic Indicators
4.3.2 Population Profile
4.3.3 Disease Profile
4.3.4 Healthcare Spending & Financing
4.3.5 Pharmaceutical Market
4.3.6 Import & Export
4.3.7 Branded & Generic Drugs
4.3.8 Therapy Areas
4.3.9 Key Players
4.4 China (Past, Present & Future Scenario)
4.4.1 Macroeconomic Indicators
4.4.2 Population Profile
4.4.3 Disease Profile
4.4.4 Healthcare Spending & Financing
4.4.5 Pharmaceutical Market
4.4.6 Import & Export
4.4.7 Branded & Generic Drugs
4.4.8 Therapy Areas
4.4.9 Key Players
4.5 Turkey (Past, Present & Future Scenario)
4.5.1 Macroeconomic Indicators
4.5.2 Population Profile
4.5.3 Disease Profile
4.5.4 Healthcare Spending & Financing
4.5.5 Pharmaceutical Market
4.5.6 Import & Export
4.5.7 Branded & Generic Drugs
4.5.8 Therapy Areas
4.5.9 Key Players
4.6 Mexico (Past, Present & Future Scenario)
4.6.1 Macroeconomic Indicators
4.6.2 Population Profile
4.6.3 Disease Profile
4.6.4 Healthcare Spending & Financing
4.6.5 Pharmaceutical Market
4.6.6 Import & Export
4.6.7 Branded & Generic Drugs
4.6.8 Therapy Areas
4.6.9 Key Players
4.7 Indonesia (Past, Present & Future Scenario)
4.7.1 Macroeconomic Indicators
4.7.2 Population Profile
4.7.3 Disease Profile
4.7.4 Healthcare Spending & Financing
4.7.5 Pharmaceutical Market
4.7.6 Import & Export
4.7.7 Branded & Generic Drugs
4.7.8 Key Players
Chapter 5 Opportunities
5.1 Chronic Diseases
5.2 Pharma Outsourcing Market
5.3 Vaccine Market
5.4 Medical Devices Market
Chapter 6 Restraining Forces
6.1 Counterfeit Drugs
6.2 Patent Protection
6.3 Traditional Medicines
Chapter 7 Key Players
7.1 GlaxoSmithKline
7.2 Sanofi-Aventis
7.3 Pfizer Inc.
7.4 Novartis
7.5 AstraZeneca
Figures
Figure 2-1 Global - Pharmaceutical Market* (in Billion US$), 2001-2007E
Figure 2-2 Global - Forecast for Pharmaceutical Market* (in Billion US$), 2008-2012
Figure 2-3 G7 Countries - Pharmaceutical Markets (in Billion US$), 2007E
Figure 2-4 G7 Countries - Forecast for Pharmaceutical Markets (in Billion US$), 2012
Figure 2-5 G7 Countries - CAGR Growth of Pharmaceutical Markets (%), 2007-2012
Figure 2-6 E7 Countries - Pharmaceutical Markets (in Billion US$), 2007E
Figure 2-7 E7 Countries - Forecast for Pharmaceutical Markets (in Billion US$), 2012
Figure 2-8 E7 Countries - CAGR Growth of Pharmaceutical Markets (%), 2007-2012
Figure 2-9 Global - Pharmaceutical Market by E7 & G7 Countries (%), 2007E & 2012F
Figure 2-10 Global - Share of E7 & G7 Countries in Pharmaceutical Market Growth (%), 2007-2012
Figure 3-1 G7 Countries - Real GDP (in Trillion US$), 2004 & 2012F
Figure 3-2 E7 Countries - Real GDP (in Trillion US$), 2004 & 2012F
Figure 3-3 Global - Share of E7 & G7 Countries in Population (%), 2007E & 2012F
Figure 3-4 Relative Per Capita Spending on Drugs by Age Group
Figure 3-5 India - Prevalence of various Lifestyle-related Diseases (in Million), 2005 & 2015F
Figure 4-1 Brazil - Nominal GDP (in Billion US$), 2005-2012F
Figure 4-2 Brazil - Consumer Price Index (%), 2005-2012F
Figure 4-3 Brazil - Currency Exchange Rate (From US$ to BRL), 2005-2012F
Figure 4-4 Brazil - Foreign Direct Investment (in Billion US$), 2004-2007
Figure 4-5 Brazil - Population (in Million), 2005-2012F
Figure 4-6 Brazil - Breakup of Population by Age Group (%), 2005-2012F
Figure 4-7 Brazil - Population in the Age Group of 65 Years & Above (in Million), 2005-2012F
Figure 4-8 Brazil - Number of Deaths due to Leading Causes (in ‘000), 2005
Figure 4-9 Brazil - Breakup of Deaths by various Causes (%), 2005-2012F
Figure 4-10 Brazil - Per Head Healthcare Spending (in US$), 2004-2012F
Figure 4-11 Brazil - Breakup of Healthcare Payment by Source (%), 2006
Figure 4-12 Brazil - Pharmaceutical Market (in Billion BRL), 2001, 2002 & 2004-2007E
Figure 4-13 Brazil - Pharmaceutical Market (in Billion Units), 2004-2007E
Figure 4-14 Brazil - Forecast for Pharmaceutical Market (in Billion BRL), 2008-2012
Figure 4-15 Brazil - Pharmaceutical Imports (in Billion US$), 2004-2007E
Figure 4-16 Brazil - Pharmaceutical Exports (in Million US$), 2004-2007E
Figure 4-17 Brazil - Generic Drugs (in Million US$), 2004-2007E
Figure 4-18 Brazil - Forecast for Generic Drugs (in Million US$), 2008-2012
Figure 4-19 Brazil - Share of Generic Drugs in Pharmaceutical Market* (%), 2007E & 2012F
Figure 4-20 Brazil - Breakup of Pharmaceutical Market by Segment (%), Dec 2007
Figure 4-21 Russia - Nominal GDP (in Billion US$), 2005-2012F
Figure 4-22 Russia - Consumer Price Index (%), 2005-2012F
Figure 4-23 Russia - Currency Exchange Rate (From US$ to RUB), 2005-2012F
Figure 4-24 Russia - Foreign Direct Investment (in Billion US$), 2004-2007
Figure 4-25 Russia - Population (in Million), 2005-2012F
Figure 4-26 Russia - Breakup of Population by Age Group (%), 2005-2012F
Figure 4-27 Russia - Population in the Age Group of 65 Years & Above (in Million), 2005-2012F
Figure 4-28 Russia - Number of Deaths due to Leading Causes (in '000), 2005
Figure 4-29 Russia - Breakup of Deaths by various Causes (%), 2005-2012F
Figure 4-30 Russia - Per Head Healthcare Spending (in US$), 2004-2012F
Figure 4-31 Russia - Breakup of Healthcare Payment by Source (%), 2005
Figure 4-32 Russia - Domestic Pharmaceutical Market (in Billion US$), 2005-2007E
Figure 4-33 Russia - Domestic Pharmaceutical Market by Segment (in Billion US$), 2005-2007E
Figure 4-34 Russia - Forecast for Domestic Pharmaceutical Market (in Billion US$), 2008-2012
Figure 4-35 Russia - Pharmaceutical Imports (in Billion US$), 2005-2007E
Figure 4-36 Russia - Breakup of Pharmaceutical Market* by Branded & Generic Drugs (%), 2005
Figure 4-37 India - Nominal GDP (in Billion US$), 2005-2012F
Figure 4-38 India - Consumer Price Index (%), 2005-2012F
Figure 4-39 India - Currency Exchange Rate (From US$ to INR), 2005-2012F
Figure 4-40 India - Foreign Direct Investment (in Billion US$), 2002-03 to 2006-07
Figure 4-41 India - Foreign Direct Investment in Pharmaceutical Market (in Million US$), 2003-04 to 2006-07
Figure 4-42 India - Population (in Million), 2005-2012F
Figure 4-43 India - Breakup of Population by Age Group (%), 2005-2012F
Figure 4-44 India - Population in the Age Group of 65 Years & Above (in Million), 2005-2012F
Figure 4-45 India - Number of Deaths due to Leading Causes (in '000), 2005
Figure 4-46 India - Breakup of Deaths by various Causes (%), 2005-2012F
Figure 4-47 India - Per Head Healthcare Spending (in US$), 2005-2012F
Figure 4-48 India - Breakup of Healthcare Payment by Source (%), 2006
Figure 4-49 India - Domestic Pharmaceutical Market* (in Billion INR), 2001-02 to 2006-07
Figure 4-50 India - Forecast for Domestic Pharmaceutical Market* (in Billion INR), 2007-08 to 2011-12
Figure 4-51 India - Pharmaceutical Imports (in Billion INR), 2000-01 to 2006-07E
Figure 4-52 India - Pharmaceutical Exports (in Billion INR), 2005-06 to 2011-12F
Figure 4-53 India - Breakup of Domestic Pharmaceutical Market by Segment (%), 2004 & 2010F
Figure 4-54 India - Share of Top Players in Pharmaceutical Market (%), 2006
Figure 4-55 China - Nominal GDP (in Billion US$), 2005-2012F
Figure 4-56 China - Consumer Price Index (%), 2005-2012F
Figure 4-57 China - Currency Exchange Rate (From US$ to CNY), 2005-2012F
Figure 4-58 China - Foreign Direct Investment (in Billion US$), 2004-2007
Figure 4-59 China - Population (in Million), 2005-2012F
Figure 4-60 China - Breakup of Population by Age Group (%), 2005-2012F
Figure 4-61 China - Population in the Age Group of 65 Years & Above (in Million), 2005-2012F
Figure 4-62 China - Number of Deaths due to Leading Causes (in '000), 2005
Figure 4-63 China - Breakup of Deaths by various Causes (%), 2005-2012F
Figure 4-64 China - Per Head Healthcare Spending (in US$), 2004-2012F
Figure 4-65 China - Breakup of Healthcare Payment by Source (%), 2006
Figure 4-66 China - Domestic Pharmaceutical Market (in Billion US$), 1996, 2000 & 2005-2007E
Figure 4-67 China - TCM Market (in Billion CNY), 2005-2007E
Figure 4-68 China - Pharmaceutical Purchase by Source (%), 2003
Figure 4-69 China - Forecast for Domestic Pharmaceutical Market (in Billion US$), 2008-2012
Figure 4-70 China - Medicine & Health Product Imports (in Billion US$), 2005-2007E
Figure 4-71 China - Breakup of Medicine & Health Product Imports by Type (%), 2006
Figure 4-72 China - Medicine & Health Product Exports (in Billion US$), 2005-2007E
Figure 4-73 China - Breakup of Medicine & Health Product Exports by Type (%), 2006
Figure 4-74 China - Breakup of Domestic Pharmaceutical Market by Segment (%), 2003
Figure 4-75 Turkey - Nominal GDP (in Billion US$), 2005-2012F
Figure 4-76 Turkey - Consumer Price Index (%), 2005-2012F
Figure 4-77 Turkey - Currency Exchange Rate (From US$ to TRY), 2005-2012F
Figure 4-78 Turkey - Foreign Direct Investment (in Billion US$), 2004-2007
Figure 4-79 Turkey - Population (in Million), 2005*-2012F
Figure 4-80 Turkey - Breakup of Population by Age Group (%), 2005*-2012F
Figure 4-81 Turkey - Population in the Age Group of 65 Years & Above (in Million), 2005*-2012F
Figure 4-82 Turkey - Number of Deaths due to Leading Causes (in '000), 2005
Figure 4-83 Turkey - Breakup of Deaths by various Causes (%), 2005-2012F
Figure 4-84 Turkey - Per Head Healthcare Spending (in US$), 2004-2012F
Figure 4-85 Turkey - Breakup of Healthcare Payment by Source (%), 2005
Figure 4-86 Turkey - Domestic Pharmaceutical Market (in Billion US$), 2005-2007E
Figure 4-87 Turkey - Domestic Pharmaceutical Market (in Million Boxes), 2002-2007E
Figure 4-88 Turkey - Forecast for Domestic Pharmaceutical Market (in Billion US$), 2008-2012
Figure 4-89 Turkey - Breakup of Pharmaceutical Market* by Imported & Locally-produced Drugs (%), 2004-2007E
Figure 4-90 Turkey - Pharmaceutical Exports (in Million US$), 2004-2007E
Figure 4-91 Turkey - Breakup of Pharmaceutical Market Sales Value* by Branded & Generic Drugs (%), 2004- 2007E
Figure 4-92 Turkey - Breakup of Pharmaceutical Market Sales Volume* by Branded & Generic Drugs (%), 2004-2007E
Figure 4-93 Mexico - Nominal GDP (in Billion US$), 2005-2012F
Figure 4-94 Mexico - Consumer Price Index (%), 2005-2012F
Figure 4-95 Mexico - Currency Exchange Rates (From US$ to MXN), 2005-2012F
Figure 4-96 Mexico - Foreign Direct Investment (in Billion US$), 2004-2007
Figure 4-97 Mexico - Population (in Million), 2005-2012F
Figure 4-98 Mexico - Breakup of Population by Age Group (%), 2005-2012F
Figure 4-99 Mexico - Population in the Age Group of 65 Years & Above (in Million), 2005-2012F
Figure 4-100 Mexico - Number of Deaths due to Leading Causes (in '000), 2005
Figure 4-101 Mexico - Breakup of Deaths by various Causes (%), 2005-2012F
Figure 4-102 Mexico - Per Head Healthcare Spending (in US$), 2004-2012F
Figure 4-103 Mexico - Breakup of Healthcare Payment by Source (%), 2004
Figure 4-104 Mexico - Domestic Pharmaceutical Market (in Billion Pesos), 2004-2007E
Figure 4-105 Mexico - Forecast for Domestic Pharmaceutical Market (in Billion Pesos), 2008-2012
Figure 4-106 Mexico - Pharmaceutical Imports (in Billion US$), 2003 & 2007E
Figure 4-107 Mexico - Pharmaceutical Exports (in Billion US$), 2003, 2006 & 2007E
Figure 4-108 Mexico - Breakup of Pharmaceutical Market* by Branded & Generic Drugs (&), 2004
Figure 4-109 Mexico - Generic Market (in Billion MXN), 2003 & 2004
Figure 4-110 Mexico - Share of Top Players in Pharmaceutical Market (%), 2007
Figure 4-111 Indonesia - Nominal GDP (in Billion US$), 2005-2012F
Figure 4-112 Indonesia - Consumer Price Index (%), 2005-2012F
Figure 4-113 Indonesia - Currency Exchange Rates (From US$ to Rp), 2005-2012F
Figure 4-114 Indonesia - Foreign Direct Investment (in Billion US$), 2005-2007
Figure 4-115 Indonesia - Population (in Million), 2005-2012F
Figure 4-116 Indonesia - Breakup of Population by Age Group (%), 2005-2012F
Figure 4-117 Indonesia - Population in the Age Group of 65 Years & Above (in Million), 2005-2012F
Figure 4-118 Indonesia - Number of Deaths due to Leading Causes (in '000), 2005
Figure 4-119 Indonesia - Breakup of Deaths by various Causes (%), 2005-2012F
Figure 4-120 Indonesia - Per Head Healthcare Spending (in US$), 2004-2012F
Figure 4-121 Indonesia - Breakup of Healthcare Payment by Source (%), 2003
Figure 4-122 Indonesia - Domestic Pharmaceutical Market (in Billion Rp), 2000-2007E
Figure 4-123 Indonesia - Prescription & OTC Drugs Market (in Billion Rp), 2000-2007E
Figure 4-124 Indonesia - Forecast for Domestic Pharmaceutical Market (in Billion Rp), 2008-2012
Figure 4-125 Indonesia - Pharmaceutical Exports (in Billion Rp) 2001-2005
Figure 4-126 Indonesia - Pharmaceutical Imports (in Billion Rp) 2001-2005
Figure 4-127 Indonesia - Breakup of Pharmaceutical Market by Branded & Generic Drugs (%), 2005
Figure 4-128 Indonesia - Share of Top Players in Prescription Pharmaceutical Market (%), 2005
Figure 4-129 Indonesia - Share of Top Players in OTC Pharmaceutical Market (%), 2005
Figure 5-1 Global - Pharma Outsourcing Market by Segment (%), 2006
Figure 5-2 BRIC Countries - Medical Device Market (in Million US$), 2006
Tables
Table 2-1 Global - Pharmaceutical Market* by Region (in Billion US$), 2006
Table 3-1 E7 Countries - Disposable Income (in Million US$), 2007E & 2012F
Table 3-2 G7 Countries - Population (in Million), 2007E & 2012F
Table 3-3 E7 Countries - Population (in Million), 2007E & 2012F
Table 3-4 G7 Countries - Population in the Age Group of 65 Years & Above (in Million), 2007E & 2012F
Table 3-5 E7 Countries - Population in the Age Group of 65 Years & Above (in Million), 2007E & 2012F
Table 4-1 Brazil - Statistics of Top 10 Players in Pharmaceutical Market, 2006
Table 4-2 Russia - Statistics of ATC Groups in Commercial Drugs Market, 2006
Table 4-3 Russia - Statistics of ATC Groups under DLO Programme, 2006
Table 4-4 Russia - Performance of Key Players in Pharmaceutical Market* (in Million US$), 2005 & 2006
Table 4-5 Russia - Performance of Key Players in Pharmaceutical Market (%), H1 2006 & H1 2007
Table 4-6 India - Performance of Drugs by Therapeutic Segment in Domestic Pharmaceutical Market (%), 2006
Table 4-7 India - Performance of Top 20 Pharmaceutical Players, 2006
Table 4-8 China - Performance* of Drugs by Therapeutic Segment in Pharmaceutical Market (%), 2005 & 2006
Table 4-9 China - Performance* of Key Players in Pharmaceutical Market (H1 2006 & H1 2007)
Table 4-10 Turkey - Performance* of Therapy Areas in Pharmaceutical Market (%), 2005 & 2006
Table 4-11 Turkey - Top 20 Pharmaceutical Players by Sales Value (Jan-Sep 2007)
Table 4-12 Turkey - Top 20 Pharmaceutical Players by Sales Volume (Jan-Sep 2007)
Table 4-13 Mexico - Performance of Therapy Areas in Retail Pharmaceutical Market, 2006
Table 5-1 India - Market for Various Chronic Diseases (in Billion INR), 2006 & 2010F
Table 5-2 India, China & Brazil - Vaccine Market (in Million US$), 2006E & 2010F
Table 7-1 GlaxoSmithKline - Key Financials (in Million US$), 2004-2006
Table 7-2 Sanofi-Aventis - Key Financials (in Million US$), 2004-2006
Table 7-3 Pfizer Inc. - Key Financials (in Million US$), 2004-2006
Table 7-4 Novartis - Key Financials (in Million US$), 2004-2006
Table 7-5 AstraZeneca - Key Financials (in Million US$), 2004 & 2005
